Anacor Pharmaceuticals (ANAC) vs. The Competition Financial Survey
Anacor Pharmaceuticals (NASDAQ: ANAC) is one of 191 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Anacor Pharmaceuticals to similar companies based on the strength of its profitability, earnings, risk, valuation, institutional ownership, analyst recommendations and dividends.
Insider and Institutional Ownership
44.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 14.5% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Anacor Pharmaceuticals and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anacor Pharmaceuticals Competitors||512||2432||6623||122||2.66|
As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.97%. Given Anacor Pharmaceuticals’ competitors higher probable upside, analysts plainly believe Anacor Pharmaceuticals has less favorable growth aspects than its competitors.
Risk and Volatility
Anacor Pharmaceuticals has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Anacor Pharmaceuticals’ competitors have a beta of 1.49, indicating that their average stock price is 49% more volatile than the S&P 500.
This table compares Anacor Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anacor Pharmaceuticals Competitors||-3,311.43%||-528.92%||-39.54%|
Valuation & Earnings
This table compares Anacor Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Anacor Pharmaceuticals Competitors||$213.37 million||-$39.02 million||-64.03|
Anacor Pharmaceuticals’ competitors have higher revenue, but lower earnings than Anacor Pharmaceuticals. Anacor Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
About Anacor Pharmaceuticals
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.
Receive News & Stock Ratings for Anacor Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anacor Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.